Table 3.
N | Homocysteine, μmol/L1 Percent relative change of homocysteine2 |
Difference in change of Homocysteine at 4 weeks by genotypes3 | Difference in change of Homocysteine at 8 weeks by genotypes3 | |||||||
---|---|---|---|---|---|---|---|---|---|---|
baseline | 4 weeks | 8 weeks | β | SE | P | β | SE | P | ||
Control | ||||||||||
AA | 130 | 12.8(1.6)[12.0] | 12.9(1.6)[11.7] | 12.9(1.6)[12.0] | ||||||
1.7(15.1) | 2.33(17.7) | ref | ref | . | ||||||
AG/GG | 22 | 12.1(1.5)[11.7] | 12.6(6.8)[1.6] | 12.6(1.5)[12.2] | ||||||
5.8(15.2) | 6.32(20.1) | 5.17 | 3.50 | 0.139 | 6.08 | 4.10 | 0.138 | |||
Total | 152 | 12.7(1.6)[12.0] | 12.8(1.6)[11.7] | 12.8(1.6)[12.0] | ||||||
2.3(15.1) | 2.9(18.0) | |||||||||
Low FA | ||||||||||
AA | 116 | 12.9(1.6)[11.5] | 11.5(1.5)[11.1]* | 11.3(1.5)[10.6] * | ||||||
-9.4(16.5) | -10.2(19.4) | ref | ref | |||||||
AG/GG | 31 | 14.1(1.5)[14.5] | 13.1(1.5)[12.3] | 12.5(1.5)[12.3] *$ | ||||||
-5.4 (15.9) | -9.6(18.3) | 3.73 | 3.33 | 0.262 | -0.06 | 3.86 | 0.989 | |||
Total | 147 | 13.2(1.6)[11.6] | 11.8(1.5)[11.3] * | 11.6(1.5)[10.8] *$% | ||||||
-8.6(16.4) % | -10.1(19.1) % | |||||||||
High FA | ||||||||||
AA | 119 | 13.7(1.6)[12.7] | 11.8(1.5)[11.4] * | 11.5(1.4)[10.8] *$ | ||||||
-12.3(16.2) | -14.4(17.3) | ref | ref | |||||||
AG/GG | 27 | 13.5(1.8)[12.9] | 11.6(1.5)[11.4] * | 11.5(1.5)[10.7] * | ||||||
-11.5(22.7) | -11.9(21.5) | 1.30 | 3.39 | 0.700 | 2.72 | 3.60 | 0.450 | |||
Total | 146 | 13.7(1.6)[12.7] | 11.7(1.5)[11.4] * | 11.5(1.5)[10.8] *% | ||||||
-12.1(17.5) % | -13.9(18.1) % |
1Geometric mean (anti-log SD), median in brackets;
2[(Homocysteine after treatment - homocysteine at baseline)/( homocysteine at baseline)]*100, Mean(SD);
3Regression model was adjusted for age, sex, BMI, baseline SBP, DBP, creatinine, TG, HDL, TC, FPG, MTHFR C677T polymorphism and study centers;
*Significantly different from baseline, P < 0.05; $Significantly different from week 4, P < 0.05;
%Significantly different from control group, P < 0.05.